Efficacy of Serratus Anterior Plane Block Mastectomy
Nyckelord
Abstrakt
Beskrivning
The aim of this study is to compare the efficacy of ultrasound-guided serratus anterior plane block with bupivacaine/ magnesium versus bupivacaine/ nalbuphine in breast cancer surgery.
Patients and methods nclusion criteria:
-ASA I and II female patients, age 25-60 undergoing breast cancer surgery
Exclusion criteria:
- Patient refusal
- Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy)
- Allergy to the drugs used in the study
- Chronic pain therapy,
- BMI more than 30 kg/m2
Datum
| Senast verifierad: | 01/31/2020 |
| Först skickat: | 05/05/2019 |
| Beräknad anmälan inlämnad: | 05/07/2019 |
| Först publicerad: | 05/09/2019 |
| Senaste uppdatering skickad: | 02/10/2020 |
| Senaste uppdatering publicerad: | 02/11/2020 |
| Faktiskt startdatum för studien: | 05/06/2019 |
| Uppskattat primärt slutdatum: | 11/30/2019 |
| Beräknat slutfört datum: | 11/30/2019 |
Tillstånd eller sjukdom
Intervention / behandling
Procedure: serratus anterior plan block
Fas
Armgrupper
| Ärm | Intervention / behandling |
|---|---|
| Active Comparator: GBM:( bupivacaine/magnesium sulphate) serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.
GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate | |
| Active Comparator: GBN: ( bupivacaine/nalpuphin) serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg. |
Urvalskriterier
| Åldrar berättigade till studier | 25 Years Till 25 Years |
| Kön som är berättigade till studier | Female |
| Accepterar friska volontärer | Ja |
| Kriterier | Inclusion Criteria: - ASA I and II female patients, age 25-60 undergoing breast cancer surgery Exclusion Criteria: - -Patient refusal - Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy) - Allergy to the drugs used in the study - Chronic pain therapy, - BMI more than 30 kg/m2 |
Resultat
Primära resultatåtgärder
1. time to first analgesic requirements in minutes [change from base line for 24 hours]
